Literature DB >> 24863090

Exercise is associated with better quality of life in patients on TSH-suppressive therapy with levothyroxine for differentiated thyroid carcinoma.

Patrícia dos Santos Vigário1, Dhiãnah Santini de Oliveira Chachamovitz2, Patrícia de Fátima dos Santos Teixeira2, Maíra de La Rocque2, Maryna Lobo dos Santos2, Mário Vaisman2.   

Abstract

OBJECTIVE: To evaluate if a supervised exercise training program improves the quality of life (QoL) of differentiated thyroid carcinoma (DTC) patients on TSH-suppressive therapy with levothyroxine (L-T4). SUBJECTS AND METHODS: Initially, a cross-sectional study was performed to compare the QoL and the health-related quality of life (HRQoL) between subclinical hyperthyroidism (SCH) patients (n = 33) and euthyroid subjects (EU; n = 49). In the prospective phase of the study, SCH patients were randomized in a non-blinded fashion to either participate (SCH-Tr = trained patients; n = 16) or not (SCH-Sed = untrained patients; n = 17) in a supervised exercise training program. The exercise program consisted of 60 minutes of aerobic and stretching exercises, twice a week, during twelve weeks. The QoL was assessed by the application of the WHOQOL-Bref, and the SF-36 was used to assess the HRQoL.
RESULTS: SCH patients had statistically lower scores than EU on the "physical" domain of WHOQOL-Bref, besides "physical function", "role-physical", "bodily pain", "general health", "vitality", "role-emotional", and "mental-health" domains of SF-36. After three months, SCH-Tr patients showed improvement in the "physical" and "psychological" domains of WHOQOL-Bref (p < 0.05), and in the "physical function", "role-physical", "bodily pain", "vitality" and "mental health" domains of SF-36.
CONCLUSION: Patients on TSH-suppressive therapy with L-T4 for DTC had impaired QoL and HRQoL compared to EU, but it was improved after 3-months of an exercise training program. Exercise seems to play an important role in the follow-up of DTC patients, since it seems to minimize the adverse effects of the treatment on QoL and HRQoL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24863090     DOI: 10.1590/0004-2730000002968

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  11 in total

1.  Optimal Thyroid Hormone Replacement.

Authors:  Jacqueline Jonklaas
Journal:  Endocr Rev       Date:  2022-03-09       Impact factor: 25.261

2.  Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Anne R Cappola; Francesco S Celi; Eric Fliers; Heike Heuer; Elizabeth A McAninch; Lars C Moeller; Birte Nygaard; Anna M Sawka; Torquil Watt; Colin M Dayan
Journal:  Eur Thyroid J       Date:  2021-02-16

Review 3.  Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Anne R Cappola; Francesco S Celi; Eric Fliers; Heike Heuer; Elizabeth A McAninch; Lars C Moeller; Birte Nygaard; Anna M Sawka; Torquil Watt; Colin M Dayan
Journal:  Thyroid       Date:  2021-02       Impact factor: 6.568

Review 4.  Long-term treatment-related morbidity in differentiated thyroid cancer: a systematic review of the literature.

Authors:  William Ae Parker; Ovie Edafe; Sabapathy P Balasubramanian
Journal:  Pragmat Obs Res       Date:  2017-05-16

Review 5.  Quality of life in thyroid cancer patients: a literature review.

Authors:  Elena Bãrbuş; Claudiu Peştean; Maria Iulia Larg; Doina Piciu
Journal:  Clujul Med       Date:  2017-04-25

6.  The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma

Authors:  Nazli Gülsoy Kirnap; Özlem Turhan Iyidir; Yusuf Bozkuş; Şerife Mehlika Işildak; Cüneyd Anil; Sevde Nur Firat; Canan Demir; Asli Nar; Neslihan Başçil Tütüncü
Journal:  Turk J Med Sci       Date:  2020-06-23       Impact factor: 0.973

7.  Systematic review of health-related quality of life following thyroid cancer.

Authors:  Emma G Walshaw; Mike Smith; Dae Kim; Jonathan Wadsley; Anastasios Kanatas; Simon N Rogers
Journal:  Tumori       Date:  2021-08-13

8.  A systematic review of health state utility values for thyroid cancer.

Authors:  Rachel Houten; Nigel Fleeman; Eleanor Kotas; Angela Boland; Tosin Lambe; Rui Duarte
Journal:  Qual Life Res       Date:  2020-10-24       Impact factor: 4.147

9.  Fatigue and quality of life among thyroid cancer survivors without persistent or recurrent disease.

Authors:  Yukari Maki; Kiyomi Horiuchi; Takahiro Okamoto
Journal:  Endocr Connect       Date:  2022-02-28       Impact factor: 3.335

10.  A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol.

Authors:  Eun Kyung Lee; Yea Eun Kang; Young Joo Park; Bon Seok Koo; Ki-Wook Chung; Eu Jeong Ku; Ho-Ryun Won; Won Sang Yoo; Eonju Jeon; Se Hyun Paek; Yong Sang Lee; Dong Mee Lim; Yong Joon Suh; Ha Kyoung Park; Hyo-Jeong Kim; Bo Hyun Kim; Mijin Kim; Sun Wook Kim; Ka Hee Yi; Sue K Park; Eun-Jae Jung; June Young Choi; Ja Seong Bae; Joon Hwa Hong; Kee-Hyun Nam; Young Ki Lee; Hyeong Won Yu; Sujeong Go; Young Mi Kang
Journal:  Endocrinol Metab (Seoul)       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.